Optimizing the management of acute ischaemic stroke: A review of the utilization of intravenous recombinant tissue plasminogen activator (tPA)

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 6, 2012, Pages 620-629

  Eissa, A ^a   Krass, I ^a   Bajorek, B V ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

alteplase; cerebrovascular accident; stroke; thrombolysis; tissue Plasminogen Activator (tPA)

Indexed keywords

ALTEPLASE;

BLEEDING; BRAIN ISCHEMIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

BRAIN ISCHEMIA; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84868352772     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01366.x     Document Type: Review

References (68)

1. Donnan G, Fisher M, Macleod M, Davis S,. Stroke. Lancet, 2008; 371: 1612-1623.
2. Rosamond W, Flegal K, Furieb K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee: heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008; 117: 25-146.
3. National Stroke Foundation. National Stroke Audit-Acute Services Clinical Audit Report 2011. Melbourne, Australia: National Stroke Foundation, 2011.
4. Mathers C, Vos E, Stevenson C, Begg S,. The burden of disease and injury in Australia. Bull World Health Organ, 2001; 79: 1076-1084.
5. Cadilhac D, Carter R, Thrift A, Dewey H,. Estimating the Long-Term Costs Of Ischemic and Hemorrhagic Stroke for Australia: New Evidence Derived From the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke, 2009; 40: 915-921.
6. National Stroke Foundation. National Stroke Audit-Acute Services Clinical Audit Report 2009. Melbourne, Australia: National Stroke Foundation, 2009.
7. Straus S, Majumdar S, McAlister F,. New evidence for stroke prevention: scientific review. J Am Med Assoc, 2002; 288: 1388-1395.
8. Bajorek B, Krass I, Ogle S, Duguid M, Shenfield G,. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc, 2005; 53: 1912-1920.
9. Albers G, Bates V, Clark W, Bell R, Verro P, Hamilton S,. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. J Am Med Assoc, 2000; 283: 1145-1150.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Eng J Med, 1995; 333: 1581-1587.
11. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. New Eng J Med, 2008; 359: 1317-1329.
12. Adams H, Del Zoppo G, Alberts M, et al. Guidelines for the early management of adults with ischemic stroke. Stroke, 2007; 38: 1655-1711.
13. Del Zoppo G, Saver J, Jauch E, Adams H,. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. Stroke, 2009; 40: 2945-2948.
14. The European Stroke Organization (ESO). Guidelines for Management of Ischaemic Stroke update 2009. Basel, Switzerland: The European Stroke Organization, 2009.
15. National Stroke Foundation. Clinical Guidelines for Stroke Management 2010. Melbourne, Australia: National Stroke Foundation, 2010.
16. Qureshi A, Suri M, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001. Neurosurgery, 2005; 57: 647-654.
17. Katzan I, Furlan A, Lloyd L, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. J Am Med Assoc, 2000; 283: 1151-1158.
18. Katzan I, Hammer M, Hixson E, Furlan A, Abou-Chebl A, Nadzam D,. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol, 2004; 61: 346-350.
19. Katzan I, Hammer M, Furlan A, Hixson E, Nadzam D,. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke, 2003; 34: 799-800.
20. Clark W, Wissman S, Albers G, Jhamandas J, Madden K, Hamilton S,. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The Atlantis Study: a randomized controlled trial. J Am Med Assoc, 1999; 282: 2019-2026.
21. Clark W, Albers G, Madden K, Hamilton S,. The rtPA (Alteplase) 0-to 6-hour acute stroke trial, Part A (A0276g) Results of a double-blind, placebo-controlled, multicenter study. Stroke, 2000; 31: 811-816.
22. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J Am Med Assoc, 1995; 274: 1017-1025.
23. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy withintravenous alteplase in acute ischaemic stroke (ECASS II). Lancet, 1998; 352: 1245-1251.
24. Steiner T, Bluhmki E, Kaste M, et al. The ECASS 3-hour cohort: secondary analysis of ECASS data by time stratification: European Cooperative Acute Stroke Study. Cerebrovasc Dis, 1998; 8: 198-203.
25. Marler J, Tilley B, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA Stroke Study. Neurology, 2000; 55: 1649-1655.
26. Ingall T, O'Fallon W, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke, 2004; 35: 2418-2424.
27. Hertzberg V, Ingall T, O'Fallon W, et al. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Clin Trials, 2008; 5: 308-315.
28. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 2004; 363: 768-774.
29. Lansberg M, Bluhmki E, Thijs V,. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic Stroke: a Metaanalysis. Stroke, 2009; 40: 2438-2441.
30. Davis S, Donnan G, Parsons M, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol, 2008; 7: 299-309.
31. Lees K, Bluhmki E, Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010; 375: 1695-1703.
32. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet, 2008; 372: 1303-1309.
33. Hill M, Buchan A,. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study (CASES). CMAJ, 2005; 172: 1307-1312.
34. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet, 2007; 369: 275-282.
35. Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke, 2008; 39: 3316-3322.
36. Johnston S, Fung L, Gillum L, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke, 2001; 32: 1061-1068.
37. Hills N, Johnston S,. Why are eligible thrombolysis candidates left untreated? Am J Prev Med, 2006; 31: S210-S216.
38. Barber P, Zhang J, Demchuk A, Hill M, Buchan A,. Why are stroke patients excluded from TPA therapy?: an analysis of patient eligibility. Neurology, 2001; 56: 1015-1020.
39. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke, 1998; 29: 18-22.
40. Wang D, Rose J, Honings D, Garwacki D, Milbrandt J,. Treating acute stroke patients with intravenous tPA: the OSF stroke network experience. Stroke, 2000; 31: 77-81.
41. Grotta J, Burgin W, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: houston experience 1996 to 2000. Arch Neurol, 2001; 58: 2009-2013.
42. Birbeck G, Cui X, Zingmond D, Vickrey B,. Intravenous tissue plasminogen activator for acute stroke in California: recipients and resources. Cerebrovasc Dis, 2004; 17: 341-343.
43. Albright K, Schott T, Jafari N, Wohlford-Wessels M, Finnerty E, Jacoby M,. Tissue plasminogen activator use: evaluation and initial management of ischemic stroke from an Iowa hospital perspective. J Stroke Cerebrovascu Dis, 2005; 14: 127-135.
44. Dick A, Straka J,. IV tPA for Acute Ischemic Stroke: results of the First 101 Patients in a Community Practice. Neurologist, 2005; 11: 305-308.
45. Bray J, Coughlan K, Bladin C,. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J, 2006; 36: 483-488.
46. Kleindorfer D, Xu Y, Moomaw C, Khatri P, Adeoye O, Hornung R,. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke, 2009; 40: 3580-3584.
47. Cadilhac D, Kilkenny M, Longworth M, Pollack M, Levi C,. The metropolitan-rural divide for stroke outcomes: do stroke units make a difference? Intern Med J, 2011; 41: 321-326.
48. Engelter S, Gostynski M, Papa S, Ajdacic-Gross V, Lyrer P,. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc Dis, 2007; 23: 211-215.
49. National Stroke Foundation. National Stroke Audit-Acute Services Organisational Survey Report 2009. Melbourne, Australia: National Stroke Foundation, 2009.
50. Mazighi M, Derex L, Amarenco P,. Prehospital stroke care: potential, pitfalls, and future. Curr Opin Neurol, 2010; 23: 31-35.
51. Grond M, Stenzel C, Schmulling S, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke, 1998; 29: 1544-1549.
52. Kahn J, Viereck J, Kase C, et al. The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke. J Emerg Med, 2005; 29: 273-277.
53. Batmanian J, Lam M, Matthews C, et al. A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust, 2007; 187: 567-570.
54. LaMonte M, Bahouth M, Magder L, et al. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial. Ann Emerg Med, 2009; 54: 319-327.
55. Kwan J, Hand P, Sandercock P,. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. QJM, 2004; 97: 273-279.
56. Ehlers L, Groth L, Bech M, Andersen G, KjÅlby M,. Organisational barriers to thrombolysis treatment of acute ischaemic stroke. Curr Med Res Opin, 2002; 23: 2833-2839.
57. Lindley R,. Thrombolysis for acute stroke in the United Kingdom. Age Ageing, 2002; 31: 28-30.
58. Kwan J, Hand P, Sandercock P,. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing, 2004; 3: 116-121.
59. Mosley I, Nicol M, Donnan G, Patrick I, Kerr F, Dewey H,. The impact of ambulance practice on acute stroke care. Stroke, 2007; 38: 2765-2770.
60. Nazir F, Petre I, Dewey H,. Introduction of an Acute Stroke Team: an effective approach to hasten assessment and management of stroke in the emergency department. J Clin Neurosci, 2009; 16: 21-25.
61. Lindsberg P, Happola O, Kallela M, Valanne L, Kuisma M, Kaste M,. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology, 2006; 67: 334-336.
62. Meurer W, Frederiksen S, Majersik J, Zhang L, Sandretto A, Scott P,. Qualitative data collection and analysis methods: The INSTINCT Trial. Acad Emerg Med, 2007; 14: 1064-1071.
63. Dirks M, Niessen L, Huijsman R, et al. Promoting acute thrombolysis for ischaemic stroke (PRACTISE). Int J Stroke, 2007; 2: 151-159.
64. Brown D, Barsan W, Lisabeth L, Gallery M, Morgenstern L,. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med, 2005; 46: 56-60.
65. Akins P, Delemos C, Wentworth D, Byer J, Schorer S, Atkinson R,. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology, 2000; 55: 1801-1805.
66. Cunningham V,. The outcome wheel: a potential tool for shared decision-making in ischemic stroke thrombolysis. CJEM, 2008; 10: 545-551.
67. Kent D, Selker H, Ruthazer R, Bluhmki E, Hacke W,. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke, 2006; 37: 2957-2962.
68. Bajorek B, Masood N, Hilmer S, Krass I,. Optimising the utilisation of antithrombotic therapy in the elderly: development and evaluation of a computerized antithrombotic risk assessment tool (CARAT). "Tools for Practice Research" Stream, Australasian Pharmaceutical Sciences Association (APSA) Annual Scientific Meeting, 8th-11th December, 2007.